Skip to main content
SpringerLink
Log in

Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three?

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Standard approaches to the systemic management of breast cancer have probably reached a plateau. Endocrine therapy leads to responses in only 1/3 of patients, probably even less ifno clinical preselection is applied, and the median benefit probably does not exceed one year. Although three-drug chemotherapeutic combinations yield responses in 55–65% of patients, the median duration of response is at best only 10 months, and addition of more drugs does not seem to offer much additional benefit. Although combining these approaches seems attractive initially, the theoretical improvement would be modest even if the effects were additive, and in fact the endocrine component may well perturb the cell cycle kinetics to reduce sensitivity to the cytotoxic component so that results would be less than additive. Clinical trials of combined chemoendocrine regimens have tended to evaluate only the initial response rate, whereas a valid comparison must consider the total response duration and survival given either combined or the usual sequential approaches. Combining endocrine and cytotoxic chemotherapies may have a greater effect when a more rational means for their amalgamation is employed. Early trials using endocrine manipulation to synchronize cell sensitivity to cytotoxic treatment have been promising. Increasing attention needs to be directed towards more innovative trial design which is respectful of the biological realities of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrated cases. Lancet 2: 104–107, 162–165, 1896

    Google Scholar 

  2. Stoll BA: Breast cancer — endocrine therapy.In Stoll BA (ed): Endocrine Therapy in Malignant Disease. WB Saunders, London, 1972, pp 111–236

    Google Scholar 

  3. McGuire WL: Physiologic principles underlying endocrine therapy of breast cancer.In McGuire WL (ed): Breast Cancer — Advances in Research and Treatment, Vol I. Plenum, New York, 1977, pp 217–262

    Google Scholar 

  4. Seibert K, Lippman ME: Hormone receptors in breast cancer.In Baum M (ed): Clinics in Oncology, Vol I, No 3. WB Saunders, London, 1982

    Google Scholar 

  5. Henderson IP, Canellos GP: Cancer of the breast — the past decade. N Engl J Med 302: 17–30, 1980

    PubMed  Google Scholar 

  6. Greenspan EM, Fieber M, Lesnick G, Edelman S: Response of advanced breast carcinoma to the combination of the antimetabolite methotrexate and the alkylating agent Thio-Tepa. J Mt Sinai Hosp NY 30: 246–267, 1963

    Google Scholar 

  7. Cooper RJ: Combination chemotherapy in hormone resistant breast cancer (abstract). Proc Am Assoc Cancer Res 10: 15, 1969

    Google Scholar 

  8. Nash CH, Jones SE, Moon TE, Davis SL, Salmon SE: Prediction of actions in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer 46: 2380–2388, 1980

    PubMed  Google Scholar 

  9. Carbone PP, Tormey DC: Combination chemotherapy for advanced disease.In McGuire WL (ed): Breast Cancer — Advances in Research and Treatment, Vol I. Plenum, New York, 1977, pp 165–215

    Google Scholar 

  10. Bull JM, Tormey DC, Li S-H, et al.: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657, 1978

    PubMed  Google Scholar 

  11. Muss HB, White DR, Richard FH: Adriamycin versus methotrexate in five drug combination chemotherapy for advanced breast cancer: a randomized trial. Cancer 42: 2141–2148, 1978

    PubMed  Google Scholar 

  12. Legha SS, Buzdar AU, Smith TL, et al.: Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Int Med 91: 847–852, 1979

    PubMed  Google Scholar 

  13. Rubens RD, Knight RK, Hayward JL, et al.: Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four drug combination. Br J Cancer 32: 730–736, 1975

    PubMed  Google Scholar 

  14. Malik R, Blumenschein GR, Legha SS, et al.: A randomized trial of high dose 5-fluorouracil, doxorubicin, and cyclophosphamide vs. conventional FAC regimen in metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 18: C-303, 1982

    Google Scholar 

  15. Tormey DC, Falkson G, Simon RM, Blom J, Bull JM, Lippman ME, Li S, Cassidy JG, Falkson H: A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 2: 247–256, 1979

    Google Scholar 

  16. Henderson IC, Gelman R, Canellos GP, Frei E: Prolonged disease-free survival in advanced breast cancer treated with ‘Super-CMF’ Adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 65 (Suppl 1): 67–75, 1981

    Google Scholar 

  17. Tormey DC, Kline J, Davis TE, et al.: Short term intensive chemohormonotherapy in metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17: C-440, 1981

    Google Scholar 

  18. Powles TJ, Coombes RC, Smith IE, et al.: Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1: 580–582, 1980

    PubMed  Google Scholar 

  19. Bonadonna G, Valagussa P: Chemotherapy of breast cancer — current views and results. Int J Rad Oncol (in press)

  20. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: The relationship between estrogen receptors and response rate of cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298: 1223–1228, 1978

    PubMed  Google Scholar 

  21. Patterson JS: Tamoxifen as an anti-cancer agent in humans.In Sutherland RL, Jordan VC (eds): Non-steroidal Antioestrogens. Academic Press, Sydney, 1981, pp 453–472

    Google Scholar 

  22. Lippman ME, Bolan G, Huff KK: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601, 1976

    PubMed  Google Scholar 

  23. Aitken SC, Lippman ME: Hormonal regulation of net DNA synthesis in MCF-7 human breast cancer cells. Cancer Res 42: 1727–1735, 1982

    PubMed  Google Scholar 

  24. Edwards DP, Adams DJ, Savage NJ, McGuire WL: Estrogeninduced synthesis of specific proteins in human breast cancer cells. Biochem Biophys Res Commun 93: 804–812, 1980

    PubMed  Google Scholar 

  25. Osborne CK: Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat 1: 121–123, 1981

    PubMed  Google Scholar 

  26. Lippman ME, Aitken SC: Estrogen and antiestrogen effects on thymidine utilization by MCF-7 human breast cancer cells in tissue culture.In Iacobelli S, King RJB, Linder HR, Lippman ME (eds): Hormones and Cancer. Raven Press, New York, 1980, pp 3–19

    Google Scholar 

  27. Weichselbaum RR, Hellman S, Piro AJ, et al: Proliferation kinetics of a human breast cancer cell line in vitro following treatment with 17β-estradiol and 1-β-D-arabinofuranosylcytosine. Cancer Res 38: 2339–2345, 1978

    PubMed  Google Scholar 

  28. Lippman ME, Cassidy J, Wesley M, Young RC: A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization (abstract). Proc Am Soc Clin Oncol 18: 305, 1982

    Google Scholar 

  29. Allegra JC, Woodcock TM, Richman SP, et al.: A phase II trial of tamoxifen, premarin, methotrexate, and 5-fluorouracil in metastatic breast cancer. Breast Cancer Res Treat 2: 93–100, 1982

    PubMed  Google Scholar 

  30. Fisher B, Redmond C, Fisher E, et al.: The contribution of recent NSABP clinical trials of primary breast cancer: an overview of findings. Cancer 46: 1009–1025, 1980

    PubMed  Google Scholar 

  31. Bonadonna G, Brusamolino E, Valagussa P, et al.: Combination chemotherapy as an adjuvant treatment in operable breast cancer. New Engl J Med 294: 405–410, 1976

    PubMed  Google Scholar 

  32. Raudin RG, Lewison EF, Slack NH, et al.: Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast cancer. Surg Gynecol Obstet 131: 1055–1064, 1970

    PubMed  Google Scholar 

  33. Dao TL, Nemoto T: Steroid receptor and response to endocrine ablations in women with metastatic cancer of the breast. Cancer 46: 2779–2782, 1980

    PubMed  Google Scholar 

  34. Meakin JW: Is there a place for adjuvant endocrine therapy of breast cancer in endocrine treatment of breast cancer? Rec Results Cancer Res 71: 178–184, 1980

    Google Scholar 

  35. Hubay CA, Pearson OH, Marshall JS, et al.: Adjuvant therapy of stage II breast cancer. Breast Cancer Res Treat 1: 77–82, 1981

    PubMed  Google Scholar 

  36. Fisher B, Redmond C, Brown A, et al.: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305: 1–6, 1981

    PubMed  Google Scholar 

  37. Fisher B, Redmond C, Brown A, Wickersham DL, Wolmark N, Allegra J, Escher G, Lippman ME, Savlov E, Wittliff J, Fisher ER, and other contributing NSABP investigators: The influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol (submitted)

  38. Ahmann FR, Jones SE: Chemo-hormonal therapy in metastatic breast cancer. Proc 26th Annual Clin Conf, MD Anderson Hospital (in press)

Download references

Authors
  1. Marc E. Lippman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for reprints: Marc E. Lippman, M.D., Head, Medical Breast Cancer Section, Medicine Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20205.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lippman, M.E. Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three?. Breast Cancer Res Tr 3, 117–127 (1983). https://doi.org/10.1007/BF01803554

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01803554

Keywords

Search

Navigation